First Brands Group debt targeted by Apollo Global Management - report
Adam H. Schechter, President and CEO of Labcorp Holdings Inc. (NYSE:LH), a $20.4 billion healthcare services provider currently trading near its 52-week high of $258.59, sold 6,121 shares of the company’s common stock on February 11, 2025. The shares were sold at an average price of $244.62, totaling approximately $1.5 million. Following this transaction, Schechter retains ownership of 86,445 shares. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
Additionally, Schechter exercised options to acquire 2,963 shares of common stock. These shares were acquired without a direct purchase price, as part of a restricted stock unit arrangement. After these transactions, Schechter’s total holdings increased to 89,408 shares. InvestingPro data shows the company maintains a strong financial health score of 2.56 (GOOD), with management actively buying back shares while maintaining relatively low price volatility.
The transactions were part of a pre-established trading plan under Rule 10b5-1, designed to allow insiders to sell stock at predetermined times. Discover more insights about Labcorp’s valuation and 8 additional exclusive ProTips with a subscription to InvestingPro, including detailed analysis of the company’s growth prospects and market position.
In other recent news, Laboratory Corporation of America (LabCorp) has been the subject of several positive developments. Truist Securities and Jefferies have both raised their price targets for LabCorp, to $285 and $290 respectively, citing strong fourth-quarter performance and promising 2025 guidance. Both firms noted LabCorp’s robust core business momentum and expected continued growth in the Diagnostics sector.
Furthermore, Evercore ISI upgraded LabCorp’s stock from "In Line" to "Outperform," indicating a positive outlook on the company’s future earnings. The firm anticipates solid growth in base testing, diagnostic margin expansion, and improvements in the Business Lines Services segment.
In addition to these analyst adjustments, LabCorp has expanded its credit facilities from $300 million to $700 million, indicating increased financial flexibility. Also, the company has released a new H5 bird flu molecular test amid a multistate outbreak, demonstrating its commitment to public health preparedness.
These recent developments underline LabCorp’s strong market position and its potential for continued growth. The raised price targets and stock upgrade reflect analysts’ confidence in the company’s future performance, while the credit facility expansion and the release of the bird flu test highlight LabCorp’s proactive approach to managing its business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.